Morgan’s Repellent® Validates Product Claims Through Independent AI Review
NEW CENTURY, Kan., Oct. 21, 2025 /PRNewswire/ — Morgan’s Repellent®, a leader in environmentally responsible pest control products known by the EPA... Read more.
MEDIA ADVISORY: Foxit to Attend EDUCAUSE 2025
Discover how Foxit’s intelligent PDF and eSignature tools help educators, administrators, and students simplify workflows, boost collaboration, and accelerate... Read more.
Improving Translational Research and Clinical Trials with Digital Pathology, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn how expert-led pathology supports translational research and clinical trials at every stage. Attendees will gain insight into how expert... Read more.
Investors Eye Next-Gen 3D AI-Imaging Technologies in Growing $9 Billion Market
NetworkNewsWire Editorial Coverage NEW YORK, Oct. 21, 2025 /PRNewswire/ — Artificial intelligence (AI) is making inroads into every corner of medical technology,... Read more.
Beyond the bench: The advantages of GMP over USP compounding in early phase development, Upcoming Webinar Hosted by Xtalks
In this free webinar, gain insights about the differences between GMP and USP compounding in research. Attendees will learn that although USP can support certain... Read more.
Immusoft Receives FDA Fast Track Designation for ISP-001, a First-in-Class Engineered B Cell Therapy for MPS I
Prospectively designed for scalability and re-dosability, Immusoft’s engineered B cells represent the next generation of advanced therapeutics SAN FRANCISCO,... Read more.
AudioEye Sets Third Quarter 2025 Earnings Call
TUCSON, Ariz., Oct. 21, 2025 /PRNewswire/ — AudioEye, Inc. (Nasdaq: AEYE) (“AudioEye” or the “Company”), the industry-leading digital... Read more.
Oakledge Advisors Launches to Help Investors Align Capital With Tomorrow’s Economy
BOSTON, Oct. 21, 2025 /PRNewswire/ — Today marks the official launch of Oakledge Advisors, a new independent advisory firm founded to help institutional investors,... Read more.
Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines
Real-world evidence (RWE) data estimate 19.8% relative vaccine effectiveness (rVE) of cell-based quadrivalent influenza vaccines (QIVc) versus standard egg-based... Read more.
LendingClub to Host and Webcast Investor Day on November 5, 2025
SAN FRANCISCO, Oct. 21, 2025 /PRNewswire/ — LendingClub Corporation (NYSE: LC), which operates America’s leading digital marketplace bank, will host... Read more.